Rua Bioscience Ltd
NZX:RUA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Rua Bioscience Ltd
Revenue
Rua Bioscience Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Rua Bioscience Ltd
NZX:RUA
|
Revenue
NZ$1.5m
|
CAGR 3-Years
297%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
BLIS Technologies Ltd
NZX:BLT
|
Revenue
NZ$12.6m
|
CAGR 3-Years
12%
|
CAGR 5-Years
4%
|
CAGR 10-Years
17%
|
|
|
A
|
AFT Pharmaceuticals Ltd
NZX:AFT
|
Revenue
NZ$236.3m
|
CAGR 3-Years
19%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
Rua Bioscience Ltd
Glance View
Rua Bioscience Ltd. operates as a pharmaceutical company that develops medical cannabis products. The company is headquartered in Gisborne, Gisborne. The company went IPO on 2020-10-22. The firm operate in the medicinal cannabis sector commercially and is focused on producing cannabinoid derived medicines. The firm is also focusing on cultivating and developing quality-assured medicinal cannabis as active pharmaceutical ingredients.
See Also
What is Rua Bioscience Ltd's Revenue?
Revenue
1.5m
NZD
Based on the financial report for Jun 30, 2025, Rua Bioscience Ltd's Revenue amounts to 1.5m NZD.
What is Rua Bioscience Ltd's Revenue growth rate?
Revenue CAGR 3Y
297%
Over the last year, the Revenue growth was 1 661%. The average annual Revenue growth rates for Rua Bioscience Ltd have been 297% over the past three years .
